Marshall on Oncology

• No-Visitor Policies Are Bad Medicine   Hospitals during the pandemic are the 'loneliest place on Earth.' Oncologist John Marshall explains why patients -- and providers -- benefit from the presence of visitors.
  Medscape Oncology, August 24, 2020
• COVID-19 Has Strengthened Pharma's Negotiating Hand   Dr John Marshall discusses the impact of COVID-19 on discussions related to drug prices.
  Medscape Oncology, July 22, 2020
• Practice-Changing GI Cancer Highlights From Virtual ASCO 2020   Gastrointestinal cancer expert Dr John Marshall gives his high-level overview of the most important developments in GI cancers, presented at the recent virtual ASCO 2020 meeting.
  Medscape Oncology, June 12, 2020
• Taking a Break From the Medical 'Service Industry'   John Marshall discusses his excitement and apprehension for his upcoming sabbatical.
  Medscape Oncology, June 07, 2019
• Molecular Profiling Is Key to GI Cancer Treatment Success   John Marshall reports on treatment trials in gastric, pancreatic, and colon cancers, from the 2019 GI Cancers Symposium.
  Medscape Oncology, February 07, 2019
• Hype, Fear of Failure Driving Immunotherapy 'Hail Mary' Treatments   John Marshall speaks with Leonard Saltz and Tanios Bekaii-Saab about the destructive trend of trying experimental drugs before having the data, and the new 'right to try' law.
  Medscape Oncology, June 14, 2018
• Practice-Changing Regorafenib Data at 2018 GI Cancers Symposium   Dr John Marshall discusses new science in pancreatic and colorectal cancers, presented at the 2018 Gastrointestinal Cancers Symposium.
  Medscape Oncology, January 31, 2018
• Celebrating the End of Chemo Can Isolate Those Not So Lucky   Dr John Marshall on how a recent symposium opened his eyes to the unintended effects of a bell-ringing ceremony at his practice.
  Medscape Oncology, January 31, 2018
• New GI Cancer Studies: Curious Failures, Hidden Gems   Dr John Marshall on recent publications, both positive and negative, that may change your practice.
  Medscape Oncology, January 03, 2018
• Clinical Trials Are 'Too Damn Complicated'   Simplifying clinical research is possible and desirable, says Dr John Marshall.
  Medscape Oncology, October 26, 2017
• Will Adjuvant Oxaliplatin Data Change Practice in CRC?   Dr John Marshall previews the GI cancer studies being presented at ASCO with his picks for the ones to watch, and predicts that a plenary presentation may be practice-changing.
  Medscape Oncology, May 26, 2017
• Mud Pies: Superfood for the Microbiome?   Too much cleanliness and sanitizing might reduce the effectiveness of our immune system, which could be a contributing cause of illness.
  Medscape Oncology, September 14, 2016
• 12 Chemo Cycles: More Toxicity Than Therapy?   Dr John Marshall suggests that 12 cycles of chemotherapy in metastatic colorectal cancer exceeds what is needed for maximum tumor regression and often results in toxicity that is better avoided.
  Medscape Oncology, July 25, 2016
• 'Can Do' Collaborations Speed Progress in GI Cancers   Dr John Marshall reports on two initiatives that harness the collective efforts of advocacy groups, academic researchers, and industry to advance research in GI cancers.
  Medscape Oncology, July 15, 2016
• HER2+ Colorectal Cancer: Slicing the Pie Into Curable Portions   Dr John Marshall views a study of dual targeting in HER2+ CRC as an argument for combining broad molecular testing and precision medicine to slice the cancer pie into curable portions.
  Medscape Oncology, May 23, 2016
• CRC Builds Up STEAM in Midst of Blizzard   After digging out from a blizzard, Dr John Marshall discusses highlights from GICS 2016, including molecular testing, new drugs, and key studies results, plus the STEAM trial in colorectal cancer.
  Medscape Oncology, February 08, 2016
• Can Physicians Help Heal the Body Politic?   Troubled by news reports of growing violence worldwide, Dr John Marshall asks: What can healthcare providers do to cool feverish minds and heal the body politic?
  Medscape Oncology, January 29, 2016
• Is Chemo Needed in Patients With MSI Colon Cancer?   FOLFOX is standard treatment for stage III colorectal cancer. But for tumors with high microsatellite instability, adjuvant chemotherapy might not be necessary, says Dr John Marshall.
  Medscape Oncology, August 10, 2015
• ASCO 2015 Raises the Question of Value   Dr John Marshall puts his vacation on hold to highlight the themes of ASCO 2015, including the critical question: What is value in cancer care, and how much is riding on the correct answer?
  Medscape Oncology, May 22, 2015
• Waves of Emotion, Understanding After PBS Cancer   Dr John Marshall asks clinicians to be mindful of the emotional response cancer patients will have to the PBS Cancer documentary--and to use heightened public awareness to push for research funding.
  Medscape Oncology, March 30, 2015